The incidence of lung cancer is increasing yearly worldwide, and targeted medicines are the main choice for lung cancer patients. However, there has been no relevant research about the analysis and adjustment of drug combinations for cancer patients with hypertension and hyperlipidemia until now. Here, we reported a case of medicine adjustment for a patient of lung cancer with hypertension and hyperlipidemia. The patient was diagnosed as right lung adenocarcinoma with lymph node metastasis and continued taking gefitinib tablets to maintain therapeutic efficacy after the end of chemotherapy. Severe paronychia and a high plasma concentration of gefitinib were noticed when the patient visited the hospital for reexamination. The clinical pharmacist found that the patient took nifedipine sustained-release tablets and simvastatin tablets simultaneously, and these medicines were all substrates of CYP3A4. The clinical pharmacist suggested replacing the medicines for hypertension and hyperlipidemia with valsartan capsules (Diovan) and rosuvastatin calcium tablets (Crestor), respectively. The adverse cutaneous reactions were greatly relieved, and the plasma concentration of gefitinib was decreased when another reexamination was performed. Therapeutic drug monitoring was an important method in our case and provided valuable information to develop individualized treatment strategies. For cancer patients suffering from other diseases such as hypertension and hyperlipidemia, it is necessary to pay special attention to the drug-drug interactions and metabolic pathways among drug combinations.

中文翻译：

---

吉非替尼联合降压降脂药治疗肺癌致严重皮肤不良反应一例报告

全球范围内肺癌发病率逐年上升，靶向药物是肺癌患者的主要选择。但目前尚未见针对合并高血压、高脂血症的癌症患者的药物组合分析与调整的相关研究。在此，我们报道一例肺癌患者合并高血压、高血脂的药物调整案例。患者被诊断为右肺腺癌并有淋巴结转移，化疗结束后继续服用吉非替尼片维持疗效。患者到医院复查时发现甲沟炎严重，吉非替尼血药浓度高。临床药师发现，患者同时服用硝苯地平缓释片和辛伐他汀片，这些药物均为CYP3A4的底物。临床药师建议将治疗高血压和高血脂的药物分别更换为缬沙坦胶囊（代文）和瑞舒伐他汀钙片（可定）。再次复查时，皮肤不良反应大大缓解，吉非替尼血药浓度下降。在我们的病例中，治疗药物监测是一种重要方法，为制定个体化治疗策略提供了有价值的信息。对于患有高血压、高脂血症等其他疾病的癌症患者，需要特别关注药物间的相互作用以及药物组合之间的代谢途径。